-
1 Comment
Dyadic International, Inc is currently in a long term downtrend where the price is trading 33.8% below its 200 day moving average.
From a valuation standpoint, the stock is 92.9% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 94.5.
Dyadic International, Inc's total revenue sank by 20.1% to $346K since the same quarter in the previous year.
Its net income has increased by 99.9% to $-2K since the same quarter in the previous year.
Finally, its free cash flow grew by 8.1% to $-1M since the same quarter in the previous year.
Based on the above factors, Dyadic International, Inc gets an overall score of 3/5.
| Exchange | NASDAQ |
|---|---|
| CurrencyCode | USD |
| ISIN | US26745T1016 |
| Sector | Healthcare |
| Industry | Biotechnology |
| PE Ratio | None |
|---|---|
| Market Cap | 26M |
| Target Price | 7 |
| Beta | 1.17 |
| Dividend Yield | None |
Dyadic International, Inc., together with its subsidiaries, a biotechnology platform company, develops, manufactures, and commercializes proteins and enzymes in the United States. The company offers Dapibus Protein Production Platform, a proprietary expression system designed to produce non-animal proteins and enzymes for non-pharmaceutical markets, including life sciences, food and nutrition, and bio-industrial sector; and C1 Protein Production Platform, a thermophilic fungal platform for large-scale production of proteins. It has a research and development agreement with VTT Technical Research Centre of Finland, Ltd; license agreement with Rubic One Health to develop various livestock vaccines; and sub-license agreement with Phibro Animal Health/Abic Biological Laboratories to develop vaccines and treatments for livestock diseases. Dyadic International, Inc. was founded in 1979 and is headquartered in Jupiter, Florida.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for DYAI using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2026